BioCentury
ARTICLE | Company News

No rejected requests under GSK transparency initiative

October 2, 2013 1:20 AM UTC

As of Sept. 20, five research proposals requesting patient-level data from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) under the pharma's January open access initiative have been approved. No request has been rejected. The four remaining submitted proposals are either being checked for compliance or are under review by an independent panel.

In April, Perry Nisen, SVP of science and innovation at GSK, told BioCentury This Week television that the initiative is the first step in GSK's evolution toward transparency. "We hope this is going to nucleate efforts amongst other sponsors to submit their data and agree to a mechanism where personalized information can be made available," said Nisen (see BioCentury This Week, April, 14). ...